China
Stealth biotech bags rights to VelaVigo bispecific in $440M deal
VelaVigo, Antibodies, Bispecific, stealth, China
U.S. Congressional Report Calls for $15 Billion to Bolster Biotech Leadership Amid Rising Chinese Competition
U.S. Biotechnology Advantage, China Biotech Competition, National Security Commission on Emerging Biotechnology, Biotechnology Investment, Biomanufacturing Strategy, U.S.-China Tech Rivalry, Bioeconomy
BioSpace Presents the World Atlas of GLP-1s
Eli Lilly, Wegovy, India, China, BioSpace, World, Cervical Atlas, GLP-1s, Nordisk, Glucagon-Like Peptide 1, Brazil, India
AstraZeneca Makes Potential $10B+ China Commitment Despite Political Pressure
Investments, China, Evaluation procedure
AstraZeneca details $2.5B investment in China’s political center, funding R&D center, biotech pacts
Investments, AstraZeneca, Beijing, China, China ‘s, Collaboration
AstraZeneca to acquire FibroGen’s China unit for $160M
China, AstraZeneca, FibroGen, FibroGen ‘s, roxadustat
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry
Illumina’s Double-Edged Sword: Navigating US-China Trade Tensions
Illumina, China, tariffs, trade tensions, DNA sequencing, unreliable entity list, biotech industry, BIOSECURE Act
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence